Drug Interaction Report

Dordaviprone and Buprenorphine: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
+

Dordaviprone

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 69 documented Dordaviprone interactions, 68 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Theoretical Effects may be stronger
The Bottom Line
Buprenorphine and dordaviprone can both prolong the QT interval, so combining them may raise the risk of an abnormal heart rhythm. Your care team will typically avoid the combination or monitor your ECG and electrolytes closely if both are needed.

Both buprenorphine and dordaviprone can affect your heart's electrical timing, something called the QT interval. When two medicines that do this are used together, the effect can add up and, in some cases, lead to an abnormal heart rhythm.

This concern is mostly theoretical right now, meaning it is based on how these drugs work rather than many reported cases. Still, it is worth taking seriously. The good news is your care team can manage this easily, usually with a simple heart tracing (ECG) and blood tests to check your electrolytes before and during treatment. Keep taking both exactly as prescribed and talk with your doctor or pharmacist about this.

Effect: Additive QT/QTc interval prolongation with increased risk of QTc-associated arrhythmias (e.g., torsades de pointes).

Mechanism: Both agents independently prolong the QT interval; dordaviprone causes concentration-dependent QTc prolongation, and buprenorphine has recognized QT-prolonging potential. Neither is a prodrug relevant here; this is a pharmacodynamic (additive) interaction.

Evidence: Theoretical. Severity: Major. Onset: Unspecified.

  • Avoid concomitant use where possible.
  • If unavoidable, separate administration.
  • Obtain baseline ECG and electrolytes, then monitor periodically.
  • Interrupt/reduce dordaviprone if QT prolongs; discontinue if life-threatening arrhythmia occurs.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

An increased risk of QT interval prolongation

Interaction Deep Dive

Do not combine dordaviprone with medications known to prolong the QT interval, since the effect on QT interval prolongation may be additive. Dordaviprone produces QTc interval prolongation that depends on concentration and can also raise the likelihood of QTc-related arrhythmias. When the combination is unavoidable, stagger the timing of dordaviprone and the QT prolonging agent. Obtain ECGs and check electrolytes before initiating dordaviprone and at regular intervals throughout therapy. For patients who experience QT prolongation, either pause treatment or lower the dordaviprone dose, and for those exhibiting evidence of life-threatening arrhythmias, stop dordaviprone permanently1.

Why it happens (mechanism)

Additive QT interval prolongation

How to manage this interaction

Your care team can manage this safely with monitoring and individualized dosing. Do not stop or change either medicine on your own.

  • Where possible, prescribers try to avoid using these two together; if both are needed, they may separate the timing of the doses.
  • Expect an ECG (heart tracing) and electrolyte blood tests before starting dordaviprone and periodically during treatment.
  • If your QT lengthens, your team may pause or lower the dordaviprone dose, adjusting it to fit you.
  • Tell your care team about dizziness, fainting, or palpitations right away.

Management is individual — confirm any change with your pharmacist or prescriber.

Common questions

Can I take Dordaviprone and Buprenorphine together?

Buprenorphine and dordaviprone can both prolong the QT interval, so combining them may raise the risk of an abnormal heart rhythm. Your care team will typically avoid the combination or monitor your ECG and electrolytes closely if both are needed. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Dordaviprone and Buprenorphine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Dordaviprone and Buprenorphine interaction managed?

Your care team can manage this safely with monitoring and individualized dosing. Do not stop or change either medicine on your own. Where possible, prescribers try to avoid using these two together; if both are needed, they may separate the timing of the doses. Expect an ECG (heart tracing) and electrolyte blood tests before starting dordaviprone and periodically during treatment. If your QT lengt… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Dordaviprone or Buprenorphine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: MODEYSO(TM) oral capsules, dordaviprone oral capsules. Jazz Pharmaceuticals, Inc. (per manufacturer), Palo Alto, CA, 2025. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.